Showing results (51-60 of 551) with videos related to
Sort By:
Pageof 56
Gynecologic and Obstetric Investigation|January 1, 1986
Thromboplastin activity in blood monocytes from oral contraceptive usersI H Omsjø, P Oian, B OsterudBlood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 1, 1992
Increased lipopolysaccharide-induced tissue factor activity and tumour necrosis factor production in monocytes after intake of aspirin: possible role of prostaglandin E2B Osterud, J O Olsen, L WilsgårdJournal of Leukocyte Biology|October 1, 1993
Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with plateletsH Halvorsen, J O Olsen, B OsterudAmerican Journal of Obstetrics and Gynecology|December 1, 1995
Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation?B Aune, P Oian, I Omsjø, et al.Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 1, 1990
Lack of ability to synthesize tissue factor by endothelial cells in intact human saphenous veinsS Solberg, B Osterud, T Larsen, et al.Spine|December 31, 1997
The inflammatory properties of contained and noncontained lumbar disc herniationO P Nygaard, S I Mellgren, B OsterudThrombosis and Haemostasis|April 1, 1997
Modulation of blood cell activation by four commonly used anticoagulantsC S Engstad, T J Gutteberg, B OsterudThrombosis and Haemostasis|July 15, 2000
Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytesB Osterud, L V Rao, J O OlsenScandinavian Journal of Haematology|March 1, 1975
The interaction of the protein and phospholipid components of tissue thromboplastin (factor III) with the factors VII and XE Bjorklid, E Storm, B Osterud, et al.Thrombosis and Haemostasis|May 1, 1995
Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTHB Osterud, M S Bajaj, S P BajajPageof 56